JP2014501707A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501707A5
JP2014501707A5 JP2013537210A JP2013537210A JP2014501707A5 JP 2014501707 A5 JP2014501707 A5 JP 2014501707A5 JP 2013537210 A JP2013537210 A JP 2013537210A JP 2013537210 A JP2013537210 A JP 2013537210A JP 2014501707 A5 JP2014501707 A5 JP 2014501707A5
Authority
JP
Japan
Prior art keywords
composition
composition according
cationic surfactant
glucagon
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013537210A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894174B2 (ja
JP2014501707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2011/052139 external-priority patent/WO2012059762A1/en
Publication of JP2014501707A publication Critical patent/JP2014501707A/ja
Publication of JP2014501707A5 publication Critical patent/JP2014501707A5/ja
Application granted granted Critical
Publication of JP5894174B2 publication Critical patent/JP5894174B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013537210A 2010-11-03 2011-11-03 グルカゴンを含む新規組成物 Expired - Fee Related JP5894174B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US40978510P 2010-11-03 2010-11-03
US40972310P 2010-11-03 2010-11-03
US61/409,723 2010-11-03
US61/409,785 2010-11-03
US201161503178P 2011-06-30 2011-06-30
US201161503104P 2011-06-30 2011-06-30
US61/503,178 2011-06-30
US61/503,104 2011-06-30
PCT/GB2011/052139 WO2012059762A1 (en) 2010-11-03 2011-11-03 Novel composition comprising glucagon

Publications (3)

Publication Number Publication Date
JP2014501707A JP2014501707A (ja) 2014-01-23
JP2014501707A5 true JP2014501707A5 (enExample) 2014-12-04
JP5894174B2 JP5894174B2 (ja) 2016-03-23

Family

ID=44913349

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537210A Expired - Fee Related JP5894174B2 (ja) 2010-11-03 2011-11-03 グルカゴンを含む新規組成物

Country Status (6)

Country Link
US (1) US9023985B2 (enExample)
EP (1) EP2635296B1 (enExample)
JP (1) JP5894174B2 (enExample)
CA (1) CA2816114C (enExample)
ES (1) ES2533601T3 (enExample)
WO (2) WO2012059762A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014096149A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 Derivatives
US9254332B2 (en) 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN107949374B (zh) * 2015-09-04 2022-04-08 莱迪杜德制药公司 稳定的胰高血糖素溶液
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
EP3463295B1 (fr) 2016-06-07 2020-08-05 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacidegreffe en bout de chaine
GB201611077D0 (en) 2016-06-24 2016-08-10 Arecor Ltd Novel composition
WO2019110837A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
WO2019110838A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US10987426B2 (en) 2017-12-07 2021-04-27 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
US11191812B2 (en) 2017-12-07 2021-12-07 Adocia Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
FR3083087A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
FR3067247A1 (fr) 2018-06-07 2018-12-14 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
AU2021277116A1 (en) * 2020-05-22 2023-02-02 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon derivative

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202607A (en) 1968-01-10 1970-08-19 Novo Terapeutisk Labor As Improvements in or relating to stable glucagon solutions and their preparation
JPH0651637B2 (ja) 1985-03-28 1994-07-06 エーザイ株式会社 ペプタイドの吸着防止組成物
EP0966271A1 (en) * 1997-11-06 1999-12-29 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
AU754740B2 (en) * 1998-06-30 2002-11-21 Takeda Chemical Industries Ltd. Pharmaceutical composition for the treatment of diabetes
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP4147234B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、カートリッジ及び吐出装置
US7115791B2 (en) 2002-12-19 2006-10-03 Exxonmobil Chemical Patents Inc. Method and apparatus for controlling effluent composition in oxygenates to olefins conversion
AU2005260025A1 (en) 2004-06-29 2006-01-12 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
JP5890085B2 (ja) 2007-01-05 2016-03-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
AU2008303948A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of the peptide Asn-Asp-Asp-Cys-Glu- Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu alone or in combination with the peptide Thr-Thr-Ser-Gln-Val- Arg-Pro-Arg as a therapeutic agent
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2490708B1 (en) 2009-10-22 2013-03-27 Biodel Inc. Stabilized glucagon solutions
US20110097386A1 (en) * 2009-10-22 2011-04-28 Biodel, Inc. Stabilized glucagon solutions

Similar Documents

Publication Publication Date Title
JP2014501707A5 (enExample)
JP2018138578A5 (enExample)
HRP20220692T1 (hr) Brzodjelujući pripravci inzulina
CO2019012773A2 (es) Sistemas autoenderezables y componentes y métodos relacionados
JP5894174B2 (ja) グルカゴンを含む新規組成物
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
HRP20251088T1 (hr) Upotreba dugodjelujućih peptida glp‑1
MX2011009174A (es) Formulaciones de insulina para captacion rapida.
MX2020009411A (es) Capsula resistente al abuso.
MX2010003776A (es) Composiciones de insulina inyectables de accion rapida.
AR092862A1 (es) Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
JP2017503017A5 (enExample)
RU2014115996A (ru) Автоматическое инъекционное устройство
JP2015512392A5 (enExample)
WO2014047657A3 (en) Drug pump devices and needle-insertion mechanisms
JP2012051891A5 (enExample)
JP2014526369A5 (enExample)
FI3479819T3 (fi) Stabiili nestemäinen farmaseuttinen valmiste
HRP20221367T1 (hr) Brzodjelujući inzulinski pripravci
MY185334A (en) Glucagon derivatives with improved stability
RU2016119746A (ru) Стабильный состав инсулина глулизин
MX2017012506A (es) Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan.
DE602006007708D1 (de) Radiopharmazeutischer container mit injektionsnadel-entkappungsvorrichtung
PE20190351A1 (es) Agente terapeutico del sindrome de hunter y metodo de tratamiento
BR112015030792B1 (pt) Dispositivo de injeção